Bullish
Gilead Sciences' stock (GILD) rose by 3.48% due to positive developments in its pipeline, particularly in HIV treatments. Key drivers include positive...
Bullish
The National AIDS Memorial and the Gilead Foundation have announced a three-year, $3 million commitment to expand HIV/AIDS education, community leader...
Neutral
Merck and Gilead Sciences announced mixed results from recent studies, including a setback in a late-stage lung cancer trial for their combined drug t...
Neutral
Merck and Gilead Sciences experienced a mixed day with a significant win in HIV treatment but a setback in cancer therapy. Their weekly HIV pill, IS/L...
Bullish
Gilead Sciences and Merck announced positive topline results from two Phase 3 trials (ISLEND-1 and ISLEND-2) for their investigational oral once-weekl...
Neutral
Merck and Gilead Sciences announced the discontinuation of their Phase 3 KEYNOTE-D46/EVOKE-03 study, which investigated Trodelvy in combination with K...
Neutral
RBC Capital has reiterated a Sector Perform rating on Gilead Sciences (NASDAQ: GILD) with a $122.00 price target, noting that while the stock trades a...
Neutral
Los Angeles Capital Management LLC reduced its stake in Gilead Sciences (NASDAQ:GILD) by 17.6% in the fourth quarter, selling 676,504 shares and retai...
Bullish
Vise Technologies Inc. increased its stake in Gilead Sciences (NASDAQ:GILD) by 32.1% in the fourth quarter, purchasing an additional 11,294 shares, br...
Neutral
PBU The Pension Fund of Early Childhood & Youth Educators recently acquired 95,333 shares of Gilead Sciences, valued at approximately $11.7 million, m...
Morgan Stanley has reiterated its "Buy" rating on Gilead Sciences (GILD.US) and maintained its target price at $168. This indicates a continued positi...
Bullish
Harvest Fund Management Co. Ltd increased its stake in Gilead Sciences, Inc. by 14.4% in the fourth quarter, acquiring an additional 13,385 shares, br...
Bullish
TD Asset Management Inc reduced its stake in Gilead Sciences (NASDAQ:GILD) by 2.0% in the fourth quarter, selling 67,251 shares and retaining 3.36 mil...
Bullish
Gilead Sciences' drug Livdelzi has new supporting evidence, as IDEAL data expands its efficacy profile to include patients with primary biliary cholan...
Bullish
Gilead Sciences released positive results from its Phase 3 IDEAL study for Livdelzi (seladelpar) in primary biliary cholangitis (PBC), showing signifi...
Gilead's Livdelzi, a treatment for primary biliary cholangitis (PBC), met its primary endpoint in a Phase 3 study, demonstrating its ability to normal...
Bullish
Gilead Sciences announced positive results from its Phase 3 IDEAL trial for Livdelzi (seladelpar) in primary biliary cholangitis (PBC), showing statis...
Gilead Sciences announced positive results from its Phase 3 IDEAL study for Livdelzi (seladelpar) in primary biliary cholangitis (PBC). The study show...
Neutral
MUFG Securities EMEA plc reduced its stake in Gilead Sciences (NASDAQ:GILD) by 53.7% in the fourth quarter, selling 58,888 shares and retaining 50,862...
Neutral
Grandfield & Dodd LLC significantly reduced its stake in Gilead Sciences, Inc. by 14.1% in the fourth quarter, selling 28,306 shares and retaining 172...